UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of exon-16-deleted HER2 in breast carcinomas

Endocrine-related cancer, 2006-03, Vol.13 (1), p.221-232

2006

Volltextzugriff (PDF)

Role of HER2/neu in tumor progression and therapy

Cellular and molecular life sciences : CMLS, 2004-12, Vol.61 (23), p.2965-2978

2004

Volltextzugriff (PDF)

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth

Annals of oncology, 2002, Vol.13 (1), p.65-72

2002

Volltextzugriff (PDF)

Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab

Annals of oncology, 2014-05, Vol.25 (5), p.1073-1074

2014

Volltextzugriff (PDF)

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

Annals of oncology, 2001, Vol.12 (suppl-1), p.S15-S19

2001

Volltextzugriff (PDF)

The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1

Endocrine-related cancer, 2005-06, Vol.12 (2), p.393-406

2005

Volltextzugriff (PDF)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

Breast cancer research and treatment, 2013-08, Vol.141 (1), p.101-110

2013

Volltextzugriff (PDF)

168 CDCP1 as a new marker of aggressiveness in triple-negative breast cancers

European journal of cancer (1990), 2014-11, Vol.50, p.56-56

2014

Volltextzugriff (PDF)

243 Triple Negative Breast Carcinoma Cells Directly Contribute to Tumor Vasculature by Endothelial Differentiation Capability

European journal of cancer (1990), 2012-07, Vol.48, p.S59-S59

2012

Volltextzugriff (PDF)

MicroRNA gene expression deregulation in human breast cancer

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7065-7070

2005

Volltextzugriff (PDF)

BHLHB3: a candidate tumor suppressor in lung cancer

Oncogene, 2008-06, Vol.27 (26), p.3761-3764

2008

Volltextzugriff (PDF)

Biologic and therapeutic role of HER2 in cancer

Oncogene, 2003-09, Vol.22 (42), p.6570-6578

2003

Volltextzugriff (PDF)

STAC3 incorporation into skeletal muscle triads occurs independent of the dihydropyridine receptor

Journal of cellular physiology, 2018-12, Vol.233 (12), p.9045-9051

2018

Volltextzugriff (PDF)

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

Annals of oncology, 2005-10, Vol.16 (10), p.1709-1709

2005

Volltextzugriff (PDF)

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

Journal of cellular physiology, 2006-05, Vol.207 (2), p.420-427

2006

Volltextzugriff (PDF)

Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (9), p.715-715

2004

Volltextzugriff (PDF)

Oncogenic protein tyrosine kinases: Role of HER2/neu in tumor progression and therapy

Cellular and molecular life sciences : CMLS, 2004-12, Vol.61 (23), p.2965-2978

2004

Volltextzugriff (PDF)

Prediction of response to therapy by biomolecular markers: from the research laboratory to the clinic

Annals of oncology, 2003-02, Vol.14 (2), p.178-179

2003

Volltextzugriff (PDF)

Role of HER2 gene overexpression in breast carcinoma

Journal of cellular physiology, 2000-02, Vol.182 (2), p.150-162

2000

Volltextzugriff (PDF)

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

Journal of cellular physiology, 2004-02, Vol.198 (2), p.259-268

2004

Volltextzugriff (PDF)

Role of putative voltage-sensor countercharge D4 in regulating gating properties of CaV1.2 and CaV1.3 calcium channels

Channels (Austin, Tex.), 2018-01, Vol.12 (1), p.249-261

2018

Volltextzugriff (PDF)

Role of HER2 in wound-induced breast carcinoma proliferation

The Lancet (British edition), 2003-08, Vol.362 (9383), p.527-533

2003

Volltextzugriff (PDF)

Abstract P4-12-06: Small HER2-positive breast carcinomas: Prognostic factors to consider in deciding on adjuvant trastuzumab treatment

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-06

2013

Volltextzugriff (PDF)

Abstract P5-07-11: CDCP1 as a new marker of aggressiveness in triple-negative breast cancers

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-07-11

2016

Volltextzugriff (PDF)

Abstract P4-12-03: Role of primary tumor molecular characteristics in identifying relapses in HER2-positive breast carcinomas adjuvantly treated with trastuzumab

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-03

2013

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(116)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(61)
Science & Technology
(57)
Life Sciences & Biomedicine
(51)
Female
(43)
Oncology
(25)
Animals
(22)
Biological And Medical Sciences
(22)
Medical Sciences
(19)
Mice
(19)
Trastuzumab
(16)
Tumors
(16)
Cell Biology
(14)
Breast Neoplasms - Drug Therapy
(13)
Breast Neoplasms - Pathology
(13)
Breast Cancer
(12)
Middle Aged
(12)
Receptor, Erbb-2 - Metabolism
(12)
Antineoplastic Agents - Therapeutic Use
(11)
Breast Neoplasms - Metabolism
(11)
Tumor Cells, Cultured
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of exon-16-deleted HER2 in breast carcinomas

Role of HER2/neu in tumor progression and therapy

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth

Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

168 CDCP1 as a new marker of aggressiveness in triple-negative breast cancers

243 Triple Negative Breast Carcinoma Cells Directly Contribute to Tumor Vasculature by Endothelial Differentiation Capability

MicroRNA gene expression deregulation in human breast cancer

BHLHB3: a candidate tumor suppressor in lung cancer

Biologic and therapeutic role of HER2 in cancer

STAC3 incorporation into skeletal muscle triads occurs independent of the dihydropyridine receptor

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors

Oncogenic protein tyrosine kinases: Role of HER2/neu in tumor progression and therapy

Prediction of response to therapy by biomolecular markers: from the research laboratory to the clinic

Role of HER2 gene overexpression in breast carcinoma

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

Role of putative voltage-sensor countercharge D4 in regulating gating properties of CaV1.2 and CaV1.3 calcium channels

Role of HER2 in wound-induced breast carcinoma proliferation

Abstract P4-12-06: Small HER2-positive breast carcinomas: Prognostic factors to consider in deciding on adjuvant trastuzumab treatment

Abstract P5-07-11: CDCP1 as a new marker of aggressiveness in triple-negative breast cancers

Abstract P4-12-03: Role of primary tumor molecular characteristics in identifying relapses in HER2-positive breast carcinomas adjuvantly treated with trastuzumab

Aktive Filter

Suchergebnisse filtern